AI is already reshaping eDiscovery review, whether a team calls it “AI” or not. Discovery is no longer a tidy set of emails and PDFs. Today’s evidence is often found inside Slack and Teams threads, mobile messages, cloud drives, audit logs, and hyperlinked “modern attachments.” The real issue for litigators is how to use AI

Editor’s Note: Autonomous weapons systems are no longer a distant concept—they are operational, data-intensive, and legally complex, presenting immediate challenges for compliance, cybersecurity, and legal professionals. As Europe accelerates its AI-driven defense initiatives, the evidence and data trails generated by these systems are becoming central to regulatory scrutiny, litigation risk, and ethical debate. This article

In this episode of Moving the Metal: The Auto Finance Podcast, hosts Brooke Conkle and Chris Capurso launch a new AI-focused segment, examining how artificial intelligence is changing auto finance through smarter chatbots and targeted advertising, digital loan applications and algorithmic decisioning, and enhanced fraud detection tools. They highlight the legal risks that come with these innovations — including unfair or deceptive acts or practices (UDAP), fair lending, bias, explainability, false positives, and increased compliance risk — and stress the importance of strong human oversight, governance, and complaint management as dealers and auto finance companies accelerate their adoption of AI in 2026.

As we head into what is anticipated to be a strong year for biopharma dealmaking, we look back at some of the biggest deals in 2025 that focus on biologics and biosimilars.
Antibody Therapy Deals
Novartis acquires Avidity Biosciences
On October 26, 2025, Novartis AG and Avidity Biosciences, Inc. announced that they had entered into